Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease

Parkinson's Disease Clinical Trial

— GLYCOPAR  

Official title:

A Randomized, Placebo-controlled, 2-arm Parallel-group Superiority Phase II Study of GLYCOpyrrolate for Moderate-to-severe Sialorrhea in PARkinson's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02382198
• Other study ID #: OttawaHRI REB 2015-0043
• Status: Recruiting
• Phase: Phase 2
• First received: January 21, 2015
• Last updated: April 13, 2018
• Start date: July 2016
• Est. completion date: December 2018

Study information

• Verified date: April 2018
• Source: Ottawa Hospital Research Institute
• Contact: Shawna Reddie
• Phone: 613-798-5555
• Email: sreddie[@]ohri.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Sialorrhea is a frequently occurring problem with detrimental effect on quality of life in 25% of PD patients. Currently, there is no intervention approved for sialorrhea in Parkinsons and evidence is only available for a 30-day effect or less. We hypothesize that glycopyrrolate will have a lasting effect in the reduction of sialorrhea in PD patients.

Description:

To assses if Glycopyrrolate has a long lasting effect on sialorrhea for patients with Parkinsons.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 28
• Est. completion date: December 2018
• Est. primary completion date: October 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

• PD as defined by United Kingdom PD Society Brain Bank criteria

• Moderate-to-severe sialorrhea defined by a score in the item 2.2 of the MDS-UPDRS greater than 2

Exclusion Criteria:

1. Other idiopathic parkinsonian syndromes, e.g., Progressive Supranuclear Palsy, Cortico-basal syndrome, or Multiple System Atrophy

2. Secondary parkinsonian syndromes (drug-induced, traumatic, encephalitic or vascular)

3. Change in antiparkinsonian medication one month prior to enrolment

4. Prior use of glycopyrrolate with or without known hypersensitivity will be considered an exclusion criterion, as it increases the risk of unblinding due to prior knowledge of potential side effects or therapeutic benefit

5. Change in the dose one month prior to enrolment of other anticholinergic agents or other drugs potentially affecting saliva production, such as tricyclic antidepressants, MAO-A inhibitors, neuroleptics (including clozapine and quetiapine more frequently used in PD) or hypnotics. These medication will remain in a constant dose throughout the trial;

6. Concomitant use of solid oral dosage forms of potassium chloride;

7. Pregnancy, breastfeeding, and premenopausal females or males not using adequate contraception; medically acceptable birth control methods for this study include: (1) Abstinence (no sexual intercourse); (2) Intrauterine device (IUD); (3) Diaphragm with spermicide; (4) Condom with spermicide; and (5) Oral contraceptives (birth control pills) + condom/diaphragm with spermicide.

8. Moderate-to-severe constipation in spite of optimal treatment (MDS-UPDRS, item 1.11>2);

9. Conditions that preclude anticholinergic therapy, e.g., documented history or symptoms suggestive of inflammatory bowel disease, glaucoma, myasthenia gravis, prostatic hypertrophy or obstructive urinary symptoms;

10. Conditions that can be exacerbated by anticholinergic effects of glycopyrrolate, e.g., documented history or symptoms suggestive of congestive heart failure, coronary heart disease, gastro-esophageal reflux disease or hyperthyroidism;

11. Uncontrolled arterial hypertension (TAS>140 mmHg or TAD>90 mmHg, using an electronic sphygmomanometer and standardized procedure16);

12. Tachyarrhythmia (interval RR <0.6 sec.);

13. TSH<0.4 mIU/L;

14. Liver dysfunction (AST, ALT, ALP >2xUpper Normal Limit);

15. Renal dysfunction (creatinine clearance <50 mL/min), as glycopyrrolate has predominant renal clearance;

16. Inability or unwillingness of subject or legal guardian/representative to give written informed consent;

17. Clinical significant lactose intolerance or known hypersensitivity to any of the study medication excipients

18. Participation in another investigational study at the time of recruitment or during the prior month.

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease
• Sialorrhea

Intervention

Drug:
• Glycopyrrolate
Drug to reduce drooling in patients with Parkinson's Decease.
• Placebo

Locations

Country	Name	City	State
Canada	The Ottawa Hospital - Civic Campus	Ottawa	Ontario
Canada	Toronto Western Hospital	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Ottawa Hospital Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean sialorrhea related-disability at end of treatment (day 90) measured by the patient/caregiver-rated ROMP-saliva.		90 days
Secondary	Mean score in sialorrhea severity at end of treatment (day 90) measured by the sialorrhea scoring scale		90 days
Secondary	Proportion of participants with a reduction of severity of sialorrhea in at least one point from baseline to end of treatment (day 90), measured by the MDS-UPDRS, item 2.2.		90 days